AAT 076Alternative Names: AAT-076; RQ-00317076
Latest Information Update: 24 Feb 2016
At a glance
- Originator RaQualia Pharma
- Class Analgesics
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Acute pain